This study aimed to evaluate the efficacy and safety of one or two cycles of blinatumomab for inducing molecular remission in pediatric patients with relapsed or refractory CD19+ pre-B ALL, followed by consolidation haploidentical HSCT. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.